NEW YORK--(BUSINESS WIRE)--Active Implants, a company that develops orthopedic implant solutions, today announced that the company’s VENUS (Verification of the Effectiveness of the NUsurface® System) trial is now underway at Lenox Hill Hospital in New York City. Lenox Hill Hospital is one of just 10 sites nationwide participating in the VENUS clinical trial to evaluate the company’s investigational meniscus implant for the treatment of persistent knee pain caused by injured or deteriorating meniscus cartilage.
The meniscus is a tissue pad between the thigh and shin bones. Once damaged, the meniscus has a very limited ability to heal. Over 1 million partial meniscectomies to remove or repair a torn meniscus are performed in the U.S. every year, about the same as the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus surgery.
“There aren’t many options for patients who experience persistent knee pain following meniscus surgery,” said Dr. Elliott Hershman, Chairman of Orthopaedic Surgery at Lenox Hill Hospital. “Damage to the meniscus can lead to arthritis and the need for knee replacement surgery. We hope this study finds that the NUsurface implant alleviates pain in these patients, as well as helps them delay or avoid knee replacement surgery.”
The VENUS study will enroll approximately 130 patients at orthopedic centers in the U.S., Europe and Israel. Participants who meet study requirements and agree to enter the trial are randomized to receive either the NUsurface device or non-surgical treatment, which is the current standard of care for patients with persistent knee pain following meniscus surgery. To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago. To learn more about the study, call (844) 680-8951 or visit www.meniscus-trial.com.
About the NUsurface® Meniscus Implant
In the U.S., the NUsurface® Meniscus Implant, from Active Implants LLC, is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. NUsurface is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissue. The NUsurface device mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. It is inserted into the knee joint through a small incision, and patients typically can go home soon after the operation. After surgery, patients undergo a six-week rehabilitation program. NUsurface has been used clinically in Europe since 2008 and Israel since 2012.
About Lenox Hill Hospital
Lenox Hill Hospital is a member of the North Shore-LIJ Health System, which is changing its name in January 2016 to Northwell Health. Lenox Hill is a 652-bed, fully accredited, acute care hospital located on Manhattan’s Upper East Side with a national reputation for outstanding patient care and innovative medical and surgical treatments. US News & World Report has ranked the hospital among the top 10 hospitals in the state of New York with a total of 6 “high performing” designations for its clinical performance in Cardiology & Heart Surgery, Gastroenterology & GI Surgery, Geriatrics, Nephrology, Orthopedics and Urology. It is also recognized nationally as a leader in maternal/child health and offers a wide range of services in radiology, and medical and surgical specialties. For more information, go to www.lenoxhillhospital.org.
To learn more about Lenox Hill Orthopaedics please visit:
https://www.northshorelij.com/find-care/locations/lenox-hill-orthopaedics/clinical-expertise
CAUTION Investigational device. Limited by United States law to investigational use.
